USA: A new study published in the Journal of Diabetes and Its Complications suggests that tirzepatide, a novel dual ...

Findings showed weekly treatment with tirzepatide significantly reduced the risk of progression to type 2 diabetes by 94% (efficacy estimand; pooled doses of 5mg, 10mg, 15mg) compared with placebo ...

Findings at week 176 demonstrated that among patients treated with tirzepatide (efficacy estimand; pooled doses of 5mg, 10mg, 15mg), 98.8% remained diabetes free, corresponding to a 94% reduction ...

176-week SURMOUNT-1 Phase 3 study in adults with pre-diabetes is the longest completed trial of tirzepatide to date Tirzepatide resulted in sustained weight loss through the treatment period ...

Tirzepatide also significantly reduced the onset of T2D, with only 1.3% of participants in the treatment groups developing T2D compared to 13.3% in the placebo group (hazard ratio = 0.07, P < 0.001).

A study published in eClinicalMedicine found that tirzepatide outperforms semaglutide in reducing the risk of type 2 diabetes and major cardiovascular events among individuals with obesity, with ...

A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight ...

Adults with prediabetes and overweight or obesity have a 94% lower risk for developing type 2 diabetes with the once-weekly GIP/GLP-1 dual agonist tirzepatide vs. placebo, according to top-line ...